These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

231 related items for PubMed ID: 16769145

  • 21. Corticotropin releasing factor receptor 1 (CRF1) and CRF2 agonists exert an anti-inflammatory effect during the early phase of inflammation suppressing LPS-induced TNF-alpha release from macrophages via induction of COX-2 and PGE2.
    Tsatsanis C, Androulidaki A, Dermitzaki E, Gravanis A, Margioris AN.
    J Cell Physiol; 2007 Mar; 210(3):774-83. PubMed ID: 17117478
    [Abstract] [Full Text] [Related]

  • 22. The CRF1 receptor mediates the excitatory actions of corticotropin releasing factor (CRF) in the developing rat brain: in vivo evidence using a novel, selective, non-peptide CRF receptor antagonist.
    Baram TZ, Chalmers DT, Chen C, Koutsoukos Y, De Souza EB.
    Brain Res; 1997 Oct 03; 770(1-2):89-95. PubMed ID: 9372207
    [Abstract] [Full Text] [Related]

  • 23. Functional, endogenously expressed corticotropin-releasing factor receptor type 1 (CRF1) and CRF1 receptor mRNA expression in human neuroblastoma SH-SY5Y cells.
    Schoeffter P, Feuerbach D, Bobirnac I, Gazi L, Longato R.
    Fundam Clin Pharmacol; 1999 Oct 03; 13(4):484-9. PubMed ID: 10456290
    [Abstract] [Full Text] [Related]

  • 24. Ethanol augments GABAergic transmission in the central amygdala via CRF1 receptors.
    Nie Z, Schweitzer P, Roberts AJ, Madamba SG, Moore SD, Siggins GR.
    Science; 2004 Mar 05; 303(5663):1512-4. PubMed ID: 15001778
    [Abstract] [Full Text] [Related]

  • 25. Autoradiographic localization of CRF1 and CRF2 binding sites in adult rat brain.
    Primus RJ, Yevich E, Baltazar C, Gallager DW.
    Neuropsychopharmacology; 1997 Nov 05; 17(5):308-16. PubMed ID: 9348546
    [Abstract] [Full Text] [Related]

  • 26. Effect of lamotrigine and carbamazepine on corticotropin-releasing factor-associated serotonergic transmission in rat dorsal raphe nucleus.
    Tanahashi S, Yamamura S, Nakagawa M, Motomura E, Okada M.
    Psychopharmacology (Berl); 2012 Apr 05; 220(3):599-610. PubMed ID: 21947356
    [Abstract] [Full Text] [Related]

  • 27. Corticotropin-releasing factor modulates maternal separation-induced ultrasonic vocalization in rat pups via activation of CRF1 receptor.
    Ise S, Nagano N, Okuda S, Ohta H.
    Brain Res; 2008 Oct 09; 1234():59-65. PubMed ID: 18703034
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Role of corticotropin releasing factor (CRF) receptors 1 and 2 in CRF-potentiated acoustic startle in mice.
    Risbrough VB, Hauger RL, Pelleymounter MA, Geyer MA.
    Psychopharmacology (Berl); 2003 Nov 09; 170(2):178-87. PubMed ID: 12845406
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Subtype-selective corticotropin-releasing factor receptor agonists exert contrasting, but not opposite, effects on anxiety-related behavior in rats.
    Zhao Y, Valdez GR, Fekete EM, Rivier JE, Vale WW, Rice KC, Weiss F, Zorrilla EP.
    J Pharmacol Exp Ther; 2007 Dec 09; 323(3):846-54. PubMed ID: 17855476
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Neurobiology of corticotropin releasing factor (CRF) receptors and CRF-binding protein: implications for the treatment of CNS disorders.
    Behan DP, Grigoriadis DE, Lovenberg T, Chalmers D, Heinrichs S, Liaw C, De Souza EB.
    Mol Psychiatry; 1996 Sep 09; 1(4):265-77. PubMed ID: 9118350
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Corticotropin-releasing factor (CRF) and the urocortins differentially regulate catecholamine secretion in human and rat adrenals, in a CRF receptor type-specific manner.
    Dermitzaki E, Tsatsanis C, Minas V, Chatzaki E, Charalampopoulos I, Venihaki M, Androulidaki A, Lambropoulou M, Spiess J, Michalodimitrakis E, Gravanis A, Margioris AN.
    Endocrinology; 2007 Apr 09; 148(4):1524-38. PubMed ID: 17194738
    [Abstract] [Full Text] [Related]

  • 38. Design of 2,5-dimethyl-3-(6-dimethyl-4-methylpyridin-3-yl)-7-dipropylaminopyrazolo[1,5-a]pyrimidine (NBI 30775/R121919) and structure--activity relationships of a series of potent and orally active corticotropin-releasing factor receptor antagonists.
    Chen C, Wilcoxen KM, Huang CQ, Xie YF, McCarthy JR, Webb TR, Zhu YF, Saunders J, Liu XJ, Chen TK, Bozigian H, Grigoriadis DE.
    J Med Chem; 2004 Sep 09; 47(19):4787-98. PubMed ID: 15341493
    [Abstract] [Full Text] [Related]

  • 39. Cocaine withdrawal enhances long-term potentiation induced by corticotropin-releasing factor at central amygdala glutamatergic synapses via CRF, NMDA receptors and PKA.
    Pollandt S, Liu J, Orozco-Cabal L, Grigoriadis DE, Vale WW, Gallagher JP, Shinnick-Gallagher P.
    Eur J Neurosci; 2006 Sep 09; 24(6):1733-43. PubMed ID: 17004937
    [Abstract] [Full Text] [Related]

  • 40. The behavioural and electrophysiological effects of CRF in rat frontal cortex.
    Zieba B, Grzegorzewska M, Brański P, Domin H, Wierońska JM, Hess G, Smiałowska M.
    Neuropeptides; 2008 Sep 09; 42(5-6):513-23. PubMed ID: 18617263
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.